Limited version - please login or register to view the entire paper.
Biopure Company Analysis
Company Analysis ?BPC is a manufacturer of blood substitutes, specifically Hemopure (Hp) for humans and Oxyglobin (Og) for the veterinary (mainly canine) market. Although Hp is expected (without guarantee) to receive FDA approval by the end of 1999, Og received approval for general use in 1997. BPC has already invested $200 million on product development and manufacturing facilities for the two products, and recently received $50 million in Venture Capital funding; thus, it has little if any short-term financial constraints. The company’s plant capacity is 300,000 units of Og, or 150,000 units of Hp. There is considerable flexibility in switching from the manufacturing of one product to another, and BPC can manufacture both at the same time (given the resulting linear func...
Company Analysis ?BPC is a manufacturer of blood substitutes, specifically Hemopure (Hp) for humans and Oxyglobin (Og) for the veterinary (mainly canine) market. Although Hp is expected (without guarantee) to receive FDA approval by the end of 1999, Og received approval for general use in 1997. BPC has already invested $200 million on product development and manufacturing facilities for the two products, and recently received $50 million in Venture Capital funding; thus, it has little if any short-term financial constraints. The company’s plant capacity is 300,000 units of Og, or 150,000 units of Hp. There is considerable flexibility in switching from the manufacturing of one product to another, and BPC can manufacture both at the same time (given the resulting linear func...
Posted by: Darren McCutchen
Limited version - please login or register to view the entire paper.